Big biotech, Big pharma, Biotech, Financing, Pharma

Gilead Sciences announces $5 billion in stock repurchase financing

Posted on 08 May 2014

Tags: ,

Gilead Sciences has authorized a repurchase of up to $5 billion of the company’s common stock.

This is in addition to a separate $5 billion buyback program announced in January 2011, which has approximately $2.9 billion remaining in the plan and is expected to be completed by September 2014.

The new program expires three years after the completion of the current repurchase program.

For further financing deal information visit Current Agreements (subscription required)



Read: more on financing deals in pharma, biotech, life science partnering deal news, insights and glossary

View: Current Partnering’s Financing Scorecard – view top life science financing deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter – reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Follow us on: LinkedIn Current Partnering | LinkedIn Business Development Network | @Currentpartner on Twitter

Print Friendly, PDF & Email

Leave a Reply